COMPASS PATHWAYS PLC (CMPS) Current Ratio
- Current ratio · latest quarter: Value 1.30×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 1.30× | Current assets / current liabilities. $475.67M ÷ $367.29M ≈ 1.30× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 475.67M USD | Assets, Current |
| Current obligations | 367.29M USD | Liabilities, Current |
| Cash and equivalents | 433.30M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | (m) | |
| Inventory | (m) | |
| Payables | 12.24M USD | Accounts Payable, Current |
| Borrowing debt due within one year | 0.00 USD | Long-term Debt, Current Maturities |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $475.67M | $367.29M | $433.30M | (m) | (m) | (m) | $12.24M | $0.00 | 1.30× |
| 2026-03-31 | $510.87M | $153.80M | $466.01M | (m) | (m) | (m) | $10.88M | $0.00 | 3.32× |
| 2025-12-31 | $191.49M | $247.79M | $149.61M | (m) | (m) | (m) | $15.22M | $17.52M | 0.77× |
| 2025-09-30 | $242.39M | $197.45M | $185.94M | (m) | (m) | (m) | $5.25M | $12.67M | 1.23× |
| 2025-06-30 | $276.40M | $31.33M | $221.88M | (m) | (m) | (m) | $10.93M | $7.98M | 8.82× |
| 2025-03-31 | $305.47M | $30.00M | $260.11M | (m) | (m) | (m) | $8.58M | $8.99M | 10.18× |
| 2024-12-31 | $201.29M | $34.02M | $165.08M | (m) | (m) | (m) | $12.28M | $5.51M | 5.92× |
| 2024-09-30 | $233.66M | $26.21M | $206.95M | (m) | (m) | (m) | $8.23M | (m) | 8.91× |
| 2024-06-30 | $265.09M | $22.03M | $228.63M | (m) | (m) | (m) | $8.20M | (m) | 12.03× |
| 2024-03-31 | $295.51M | $19.40M | $262.89M | (m) | (m) | (m) | $9.34M | (m) | 15.23× |
| 2023-12-31 | $261.30M | $19.60M | $220.20M | (m) | (m) | (m) | $5.89M | $0.00 | 13.33× |
| 2023-09-30 | $284.81M | $15.35M | $248.04M | (m) | (m) | (m) | $4.25M | (m) | 18.55× |
| 2023-06-30 | $193.60M | $12.78M | $148.23M | (m) | (m) | (m) | $1.98M | (m) | 15.15× |
| 2023-03-31 | $167.83M | $11.25M | $117.10M | (m) | (m) | (m) | $3.88M | (m) | 14.91× |
| 2022-12-31 | $191.65M | $15.60M | $143.21M | (m) | (m) | (m) | $4.76M | (m) | 12.29× |
| 2022-09-30 | $218.45M | $29.53M | $173.08M | (m) | (m) | (m) | $19.89M | (m) | 7.40× |
| 2022-06-30 | $231.99M | $13.23M | $207.18M | (m) | (m) | (m) | $3.35M | (m) | 17.53× |
| 2022-03-31 | $266.55M | $11.68M | $243.68M | (m) | (m) | (m) | $2.05M | (m) | 22.82× |
| 2021-12-31 | $295.30M | $15.11M | $273.24M | (m) | (m) | (m) | $2.56M | (m) | 19.55× |
| 2021-09-30 | $312.80M | $9.32M | $293.96M | (m) | (m) | (m) | $2.74M | (m) | 33.55× |
| 2021-06-30 | $334.04M | $7.80M | $316.33M | (m) | (m) | (m) | $3.89M | (m) | 42.82× |
| 2020-12-31 | $202.40M | $6.89M | $190.33M | (m) | (m) | (m) | $2.75M | (m) | 29.36× |
| 2019-12-31 | $32.17M | $23.87M | $24.97M | (m) | (m) | (m) | $1.26M | (m) | 1.35× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |